Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E.

Surgery. 2006 Dec;140(6):960-6; discussion 966-7.

PMID:
17188145
2.

Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.

Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS.

Thyroid. 2009 Sep;19(9):953-6. doi: 10.1089/thy.2008.0371.

PMID:
19678746
3.
5.

[Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].

Martín T, Torres A, Cambil T, Castro J.

Med Clin (Barc). 2008 Oct 4;131(11):435. Spanish. No abstract available.

PMID:
18928727
6.

Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.

Philips JC, Petite C, Willi JP, Buchegger F, Meier CA.

Nucl Med Commun. 2004 Dec;25(12):1183-6.

PMID:
15640776
7.

Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.

Rosenbaum-Krumme SJ, Freudenberg LS, Jentzen W, Bockisch A, Nagarajah J.

Clin Nucl Med. 2012 Mar;37(3):e47-52. doi: 10.1097/RLU.0b013e3182443ca6.

PMID:
22310270
8.

Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD.

N Engl J Med. 1997 Sep 25;337(13):888-96.

9.

A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer.

Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, Zhu C.

Nucl Med Commun. 2007 Apr;28(4):251-5.

PMID:
17325586
10.

[Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake].

Elola M, Yoldi A, Emparanza JI, Matteucci T, Bilbao I, Goena M.

Rev Esp Med Nucl. 2011 Jul-Aug;30(4):241-3. doi: 10.1016/j.remn.2010.08.005. Epub 2011 Feb 18. Spanish.

11.

Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

Fröhlich E, Machicao F, Wahl R.

Endocr Relat Cancer. 2005 Jun;12(2):291-303. Erratum in: Endocr Relat Cancer. 2005 Sep;12(3):681.

12.

Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma.

Shinohara S, Kikuchi M, Suehiro A, Kishimoto I, Harada H, Hino M, Ishihara T.

Jpn J Clin Oncol. 2015 May;45(5):427-32. doi: 10.1093/jjco/hyv021. Epub 2015 Feb 26.

PMID:
25724214
13.

Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.

Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, Fard-Esfahani A, Fallahi B, Beiki D.

Nucl Med Commun. 2006 Jul;27(7):567-72.

PMID:
16794517
14.

A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, Neychev V, Kebebew E.

Clin Endocrinol (Oxf). 2017 Jan;86(1):128-133. doi: 10.1111/cen.13154. Epub 2016 Sep 8.

PMID:
27392538
15.

18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.

Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.

J Nucl Med. 2007 Feb;48(2):221-6. Erratum in: J Nucl Med. 2007 Mar;48(3):412. Bencherif, Badreddine B [corrected to Bencherif, Badreddine].

16.
18.

Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.

Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.

Am J Surg. 2000 Jun;179(6):457-61.

PMID:
11004330
20.

Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose.

Phan TT, van Tol KM, Links TP, Piers DA, de Vries EG, Dullaart RP, Jager PL.

Ann Nucl Med. 2004 Dec;18(8):641-6.

PMID:
15682843

Supplemental Content

Support Center